Albert J Robichaud

President and Head of Research and Development @ Tortugas Neuroscience

About

Direct the scientific and managerial aspects of a pharma research group. Primary focus is in the Central nervous systems disorders with a greater emphasis on synaptic transmission and neuroinflammation Specialties: Organic Chemistry Medicinal Chemistry Neuroscience Translational Medicine and Imaging Agents Drug Pharmacokinetics Receptor Pharmacology

Country

United States

City

Cambridge

Industry

Venture Capital & Private Equity

Skill

Medicinal Chemistry, Lead Change, Organic Chemistry, Drug Discovery, Neuroscience, Biotechnology, Biochemistry, ADME, Clinical Development, Chemistry, Analytical Chemistry, Assay Development, Drug Design, Drug Development, HPLC

Experience

President and Head of Research and Development

Tortugas Neuroscience

2026-5 - Present · 5 mos

Venture Partner

Cure Ventures

2026-5 - 2026-5 · 1 mo

Partner

Cure Ventures

2024-1 - 2026-5 · 2 yrs 5 mos

Boston, MA

Scientist

73 R&D Consulting

2023-10 - 2024-1 · 4 mos

United States

Consultant to all things in Pharma Research and Development, Scientific Advisor specializing in Neuroscience R&D.

Chief Scientific Officer

Sage Therapeutics

2011-11 - 2023-9 · 11 yrs 11 mos

Cambridge, MA

SAGE Therapeutics is a central nervous system (CNS) product focused company developing new therapies to meet the growing unmet need in a range of CNS disorders. The company was launched in October 2011 with headquarters in Cambridge, MA.

Vice President

Lundbeck Research, USA

2010-1 - 2011-11 · 1 yr 11 mos

VP of the Chemical & Pharmacokinetic Sciences group in Paramus NJ. The dept is responsible for all chemistry, modeling, and pharmacokinetics research and support for all programs within the Lundbeck US research portfolio.